About US
Contact us
-
Sanofi and Boehringer Ingelheim sign contract to $25bn business swapFrench drug maker Sanofi and German-based Boehringer Ingelheim have signed contracts in a bid to secure the strategic transaction that includes an exchange of Sanofi's animal health business Merial an2016/6/30
-
Should pharma scrap per-pill pricing completely?What if, instead of cutting drug prices, the pharma industry threw out the rulebook altogether? That’s just what a European trade group is proposing,Reutersreports, in a plan that would dump per-pill2016/6/29
-
Merck, Pfizer amp up ertugliflozin outcomes study as SGLT2 med scores in PhIIINEW ORLEANS--Merck & Co. and Pfizer are doubling down on their ertugliflozin cardiovascular outcomes study as rival SGLT2 med Jardiance continues to generate buzz for its recent score in a heart-s2016/6/29
-
Novo's weekly GLP-1 aces two head-to-head trials against Januvia, BydureonNEW ORLEANS--Novo Nordisk has staked out a big portion of its pipeline for semaglutide, the once-weekly GLP-1 drug that could follow in the footsteps of its blockbuster daily, Victoza. And this weeken2016/6/28
-
Merck's Keytruda tops chemo in first-line lung cancer trialMerck & Co. just scored a point in its immuno-oncology rivalry against Bristol-Myers Squibb. The PD-1 checkpoint inhibitor Keytruda hit its goals in a new trial in previously untreated non-small c2016/6/28
-
AstraZeneca, Teva settle Byetta patent suit; generics on their wayImmediately following AstraZeneca’s big FluMist setback Thursday, the British pharma has entered into an agreement with Teva that will likely lead to sales losses for another product, Byetta. AstraZe2016/6/27
-
Pharma accuses payers of using cash to sway U.S. cost watchdogDrugmakers haven’t much cared for a Boston-based nonprofit’s cost-effectiveness assessments of their drugs--especially considering that the group usually turns out “too pricey” verdicts. And now, they2016/6/27
-
New report says leukaemia has largest active development pipelineLeukaemia has the largest pipeline in active development from the three major indications within haematological cancer, also comprising lymphoma and myeloma, according to a new report by GBI Research.2016/6/24
-
Orion and Asahi Kasei reach agreement for pain management assetsFinnish pharmaceutical and diagnostics company Orion has entered into a global strategic collaboration agreement with Japan-based Asahi Kasei Pharma to discover, develop and commercialise assets in pa2016/6/24
-
AbbVie, Eisai and EA Pharma receive additional approval for new Humira dosing regimenAbbVie GK, the Japanese subsidiary of AbbVie, Eisai and its subsidiary EA Pharma have received the additional approval for a new dosing regimen of Humira Pre-filled Syringe 40mg / 0.8mL for Subcutaneo2016/6/23